Orchid Chemicals & Pharmaceuticals Ltd.
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012
					(Rs.Lakhs)
		Standalone
S.No	Particular	Unaudited			Audited
		Three months ended 30-Jun-12	Three months ended 31-March-12	Three months ended 30-June-11	Year ended 31-Mar-12
1	Income from Operations
	a) Net Sales / Income from Operations (Net of Excise Duty)	31563.15	45191.75	37376.02	170170.80
	b) Other operating Income	4159.90	3886.51	982.87	6293.47
	c) Total income from operations (Net)	35723.05	49078.26	38358.89	176464.27
2	Expenses
	a) Cost of materials consumed	10193.28	18573.79	21978.82	80241.50
	b) Purchases of stock-in-trade	1538.32	1054.91	1435.55	4546.38
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	7204.14	1124.96	(4846.40)	(6201.86)
	d) Employee benefit expense	3761.80	4004.85	3866.78	15464.59
	e) Depreciation / Amortisation	3991.26	4041.37	3530.47	14905.56
	f) Other Expenses	7444.46	15369.14	7226.60	41242.32
	g) Total Expenses	34133.26	44169.02	33191.82	150198.49
3	Profit/ (Loss) from operations before other income, finance costs, exceptional items (1-2)	1589.79	4909.24	5167.06	26265.78
4	Other Income	-	0.29	-	1.59
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	1589.79	4909.53	5167.06	26267.37
6	Finance costs	7132.59	5878.55	3074.74	17905.29
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(5542.80)	(969.02)	2092.32	8362.08
8	Exceptional Items - Gain / (Loss)	(808.04)	(228.73)	(107.26)	(8388.14)
9	Profit/(Loss) from ordinary activities before Tax (7+8)	(6350.84)	(1197.75)	1985.06	(26.06)
10	Tax expenses
	- Current Tax & Deferred Tax	(1270.66)	(3252.87)	430.82	(2337.22)
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(5080.18)	2055.12	1554.24	2311.16
12	Extraordinary item (net of tax expenses Rs.nil)	-	-	-	8000.00
13	Net Profit/(Loss) for the period (11+12)	(5080.18)	2055.12	1554.24	10311.16
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7044.21	7044.21	7044.21
15	Reserves excluding Revaluation Reserves	-	-	-	112410.89
16	Earnings per share (EPS) before extra-ordinary items of Rs.10/- each
	- Basic Rs.	(7.21)*	2.92*	2.21*	3.28
	- Diluted Rs.	(7.21)*	2.92*	1.82*	3.24
17	Earnings per share (EPS) after extra-ordinary items of Rs.10/- each
	- Basic Rs.	(7.21)*	2.92*	2.21*	14.64
	- Diluted Rs.	(7.21)*	2.92*	1.82*	14.46
A	PARTICULARS OF SHAREHOLDING
1	Public Shareholding
	- Number of equity shares	47611295	47601295	48939460	47601295
	- Percentage of Shareholding	67.58	67.57	69.47	67.57
2	Promoters and Promoter group shareholding
	a. Pledged / Encumbered
	- Number of shares	17110383	17060383	15745383	17060383
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	74.91	74.69	73.23	74.69
	- Percentage of shares (as a % of the total share capital of the company)	24.29	24.22	22.35	24.22
	b. Non - Encumbered
	- Number of shares	5730398	5780398	5757233	5780398
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	25.09	25.31	26.77	25.31
	- Percentage of shares (as a % of the total share capital of the company)	8.13	8.21	8.18	8.21
B	INVESTOR COMPLAINTS		3 Months ended 30-Jun-2012
	Pending at the beginning of the quarter		-NIL-
	Received during the quarter		3
	Disposed of during the quarter		3
	Remaining unresolved at the end of the quarter		-NIL-
	* EPS for the period (not annualised)
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2012 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.
2	The Company is operating in single segment (i.e) "Pharmaceuticals".
3	During the quarter, the Company formed a new subsidiary namely Orchid Pharma Singapore Private Limited in Singapore.
4	Consolidated Results of the company	Three months ended 30-Jun-12	Three months ended 31-March-12	Audited year ended 30-June-11	Year ended 31-March-12
	Total Operating Income	40670.74	49019.14	44923.21	190199.09
	EBIDTA (Before Exceptional Item)	5410.90	8867.21	9068.79	41280.65
	Profit After Tax	(5402.51)	1522.67	1692.25	9747.84
5	Exceptional items for the quarter ended June 30, 2012 represents exchange loss on FCCBs / FCTLs of Rs. 808.04 lakhs (Corresponding quarter - Loss of Rs. 107.26 lakhs). The Company had exercised the option provided under the Amendment to the Companies (Accounting Standards) Amendments Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 29th December 2011 has extended the amortisation of gains or losses arising on reporting of Foreign Currency Monetary items over the balance period of such long term asset / liability. Accordingly Exchange Loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortized in the financial statements as at June 30, 2012 on account of exercising the above option is Rs.11321.20 lakhs (Corresponding quarter - Rs.Nil).
6	The Allottment Committee of the Board has allotted 10,000 shares to an employee at an adjusted price of Rs.166.15 under Orchid - ESOP 2010 Scheme on May 17, 2012.
7	Previous period figures have been regrouped wherever necessary.
For and on behalf of the Board
Place : Chennai Date : August 14, 2012 K. Raghavendra Rao Chairman & Managing Director